Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | FPR1 | P21462 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21245460 | 0.87 | TP53 (0.48) | TP53EPHX2MAPTALDH1A1HIF1A | |
| SCHEMBL20113811 | 0.86 | TP53 (0.64) | TP53EPHX2MAPTTRPV1POLB | |
| SCHEMBL20113814 | 0.83 | TP53 (0.73) | TP53MAPTMEN1KMT2ATRPV1 | |
| SCHEMBL20120050 | 0.81 | TP53 (0.51) | TP53EPHX2MAPTHIF1AMEN1 | |
| SCHEMBL20114216 | 0.81 | TP53 (0.59) | TP53MAPTSMN1; SMN2POLB | |
| SCHEMBL20114220 | 0.80 | TP53 (0.55) | TP53MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL20120048 | 0.80 | TP53 (0.53) | TP53MAPTMEN1KMT2APOLB | |
| SCHEMBL20113815 | 0.80 | TP53 (0.60) | TP53MAPTALDH1A1POLB | |
| SCHEMBL20113810 | 0.80 | TP53 (0.54) | TP53MAPTALDH1A1SMN1; SMN2POLB | |
| SCHEMBL20120057 | 0.80 | TP53 (0.54) | TP53EPHX2MAPTHIF1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248779-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248779-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, SCNN1B, SCNN1G | TP53 1387/4885EPHX2 1886/4885FPR1 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.